

Cover Story
By Matthew Bin Han Ong
Summer of 2020 was supposed to be a brief period of respite between Wave 1 and Wave 2 of COVID-19, but out of sheer stubbornness, for reasons political, or both, SARS-CoV-2 didn't get the message.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research - Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale
- FDA clears a way for dramatic reduction in animal toxicology studies in cancer
















